CTLA4 and non-small cell lung carcinoma: Immunotherapy with the detection of immune checkpoint inhibitors (ICIs) such as programmed cell death protein 1(PD-1), programmed cell death receptor-legend 1(PD-L1) and cytotoxic T-lymphocyte-associated protein 4(CTLA-4) stirred up ripples in the in the field of neoadjuvant therapy for NSCLC (15–17).